We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sharp price spikes for some orphan generics may be getting all of the attention today, but they have little real impact on overall prescription drug prices. Read More
The FDA is not in the business of regulating drug prices, CDER Director Janet Woodcock told a Senate committee Jan. 28, pushing back against criticism that the FDA should tackle rising drug prices. Read More
In his fiscal year 2017 budget, President Barack Obama says he will seek more than $1 billion in mandatory funding over two years to help combat prescription opioid abuse. Read More
Two Oregon supplement makers are in the FDA’s crosshairs for marketing their products for a range of unapproved conditions, including regulating blood pressure and alleviating panic attacks. Read More
Turing Pharmaceuticals and Valeant Pharmaceuticals lined “their pockets at the expense of some of the most vulnerable families in our nation,” House Oversight Committee Ranking Member Elijah Cummings (D-Md.) says in a memo to committee members. Read More